[The latest review of therapeutic angiogenesis using angiogenic growth factors to peripheral arterial diseases].
Therapeutic angiogenesis using angiogenic growth factors is expected to be a new treatment of patients with severe ischemic diseases. Indeed, human gene therapy for peripheral arterial disease(PAD) using VEGF gene demonstrated the beneficial effects. In contrast, we have reported the potent angiogenic activity of hepatocyte growth factor (HGF) in animal study and we planned gene therapy for ASO and Buerger disease using HGF gene (TREAT-HGF). In a prospective, open-labeled clinical trial, we investigated the safety and biological efficiency of this gene therapy in patients with peripheral arterial disease(PAD) who had failed conventional therapy.
Aoki
Motokuni
M
Department of Geriatric Medicine, Osaka University Graduate School of Medicine.
Ogihara
Toshio
T
Morishita
Ryuichi
R
D001162:Arteriosclerosis Obliterans / Q000628:therapy*; D002986:Clinical Trials as Topic; D016228:Endothelial Growth Factors / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D017228:Hepatocyte Growth Factor / Q000235:genetics*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics*; D008222:Lymphokines / Q000235:genetics*; D018919:Neovascularization, Physiologic / Q000235:genetics*; D013919:Thromboangiitis Obliterans / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D017228:Hepatocyte Growth Factor